Cellular requirements for the suppression of leucocyte adherence inhibition reactions by serum factors from tumour-bearing mice. 1986

V K Kuchroo, and W J Halliday

Tumour-bearing mice produce circulating serum factors that block cell-mediated immunological reactions in vitro. The mechanism by which these specific suppressor factors (SF) block leucocyte adherence inhibition (LAI) was studied. It had previously been shown that the antigen-reactive effector cells in the LAI assay are Ly-1+ T cells. We have now found that Ly-2+, I-J+ cells are required in the reactive cell population to observe the blocking action of SF from serum. Tumour-bearer spleen cells (containing Ly-2+, I-J+ lymphocytes) reacted only with the specific tumour-related serum factor (SF1) and relevant tumour antigen, to produce a non-specific suppressor factor (SF2). Specificity studies were conducted with contact-sensitized mice: hapten-specific spleen cells reacted only with hapten-related SF1 and the relevant hapten, to produce a similar SF2. SF2 differed from SF1 in suppressing allogeneic as well as syngeneic cells, in suppressing populations depleted of Ly-2+, I-J+ cells, and in being unaffected by absorption with immobilized anti-I-J antibody. Gel-filtration of SF2 revealed two forms of differing MW (greater than 190,000 and 20,000-50,000).

UI MeSH Term Description Entries
D007108 Immune Tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc. Immunosuppression (Physiology),Immunosuppressions (Physiology),Tolerance, Immune
D007957 Leukocyte Adherence Inhibition Test Test for cell-mediated antitumor immunity and related serum blocking factors based on the finding that leukocytes from cancer patients, but not from controls, when mixed in vitro with antigenic extracts of tumors of the same histological type, undergo a diminution in their normal adherence to glass surfaces. Sera from tumor-bearing patients block the LAI reaction of their own leukocytes or those of other patients with the same type of tumor. LAI Test,LAI Tests,Test, LAI,Tests, LAI
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008808 Mice, Inbred CBA An inbred strain of mouse that is widely used in BIOMEDICAL RESEARCH. Mice, CBA,Mouse, CBA,Mouse, Inbred CBA,CBA Mice,CBA Mice, Inbred,CBA Mouse,CBA Mouse, Inbred,Inbred CBA Mice,Inbred CBA Mouse
D002448 Cell Adhesion Adherence of cells to surfaces or to other cells. Adhesion, Cell,Adhesions, Cell,Cell Adhesions
D005354 Fibrosarcoma A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed) Fibrosarcomas
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D000961 Antilymphocyte Serum Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS. It is used both as a test for HISTOCOMPATIBILITY and therapeutically in TRANSPLANTATION. ATGAM,Antilymphoblast Globulins,Antilymphocyte Antibodies,Antilymphocyte Globulin,Lymphocytotoxic Antibodies,Anti-Thymocyte Globulin,Antilymphocyte Immunoglobulin,Antithymocyte Globulin,Antithymoglobulin,Lymphocyte Immune Globulin, Anti-Thymocyte Globulin,Lymphocyte Immune Globulin, Anti-Thymocyte Globulin (Equine),Pressimmune,Anti Thymocyte Globulin,Anti-Thymocyte Globulins,Antibodies, Antilymphocyte,Antibodies, Lymphocytotoxic,Antibody, Antilymphocyte,Antibody, Lymphocytotoxic,Antilymphoblast Globulin,Antilymphocyte Antibody,Antilymphocyte Globulins,Antilymphocyte Immunoglobulins,Antilymphocyte Serums,Antithymocyte Globulins,Antithymoglobulins,Globulin, Anti-Thymocyte,Globulin, Antilymphoblast,Globulin, Antilymphocyte,Globulin, Antithymocyte,Globulins, Anti-Thymocyte,Globulins, Antilymphoblast,Globulins, Antilymphocyte,Globulins, Antithymocyte,Immunoglobulin, Antilymphocyte,Immunoglobulins, Antilymphocyte,Lymphocyte Immune Globulin, Anti Thymocyte Globulin,Lymphocytotoxic Antibody,Serum, Antilymphocyte,Serums, Antilymphocyte
D013491 Suppressor Factors, Immunologic Proteins, protein complexes, or glycoproteins secreted by suppressor T-cells that inhibit either subsequent T-cells, B-cells, or other immunologic phenomena. Some of these factors have both histocompatibility (I-J) and antigen-specific domains which may be linked by disulfide bridges. They can be elicited by haptens or other antigens and may be mass-produced by hybridomas or monoclones in the laboratory. Immunologic Suppressor Factors,Suppressor T-Cell Factors,T-Cell Suppressive Factors,T-Suppressor Factors,Factors, Immunologic Suppressor,Factors, T Suppressor,Suppressor Factor (SF4),T Cell Suppressor Factors,Factors, Suppressor T-Cell,Factors, T-Cell Suppressive,Factors, T-Suppressor,Suppressive Factors, T-Cell,Suppressor Factors, T,Suppressor T Cell Factors,T Cell Suppressive Factors,T Suppressor Factors,T-Cell Factors, Suppressor

Related Publications

V K Kuchroo, and W J Halliday
November 1974, European journal of cancer,
V K Kuchroo, and W J Halliday
October 1980, British journal of cancer,
V K Kuchroo, and W J Halliday
August 1976, British journal of cancer,
V K Kuchroo, and W J Halliday
May 1978, Lancet (London, England),
V K Kuchroo, and W J Halliday
January 1980, Archives roumaines de pathologie experimentales et de microbiologie,
V K Kuchroo, and W J Halliday
August 1985, The Japanese journal of experimental medicine,
V K Kuchroo, and W J Halliday
May 1972, International journal of cancer,
Copied contents to your clipboard!